



## Planning meeting with the US FDA confirmed

**Perth, Australia & Malta – 12 May 2017** – Neurotech International Limited (ASX: NTI) (“Neurotech” or the “Company”), developer of quality medical solutions in the neuroscience space, has confirmed the planning meeting with the United States Food and Drug Administration (**FDA**).

Following filing of the pre-submission package with the FDA in March 2017, the Company has received confirmation that the planning meeting with the FDA has been scheduled for June 2017. The meeting is a key step in working cooperatively with the FDA on the Company’s regulatory and clinical plan to support FDA clearance of Mente Autism, and is expected to provide the Company with targeted feedback from the FDA regarding a range of topics, such as product development, planned non-clinical evaluations and proposed data requirements, prior to making a submission to the FDA.

Neurotech also expects to clarify FDA’s marketing requirements for the technology at the meeting. Neurotech is currently envisaging marketing Mente Autism as a Class II regulated device in the US, supported by clinical data.

-ends-

### About Neurotech

Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech’s primary mission is to improve the lives of people with neurological conditions, with a vision of becoming the global leader in home-use and clinical neurotechnology solutions that are both accessible and affordable. Through flagship device Mente Autism and its associated platform, Neurotech is focused on the development and commercialisation of technological solutions for the diagnosis and treatment of such conditions, starting with autism.

Mente Autism is a clinical-quality EEG device that uses neurofeedback technology to help children with ASD. Designed for home use, Mente Autism helps relax the minds of children on the spectrum which in turns helps them to focus better and engage positively with their environment.

For more information about Neurotech and Mente Autism please visit:

<http://www.neurotechinternational.com>.

<http://www.mentetech.com>.

*For more information please contact:*

Matthew Wright

[matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

Tel: +61 451 896 420

---

### Neurotech International Ltd

ABN 73 610 205 402

Level 14, 191 St Georges Terrace

Perth, Western Australia 6060

[www.neurotechinternational.com](http://www.neurotechinternational.com)